OOIR: Observatory of International Research

Papers

(The median citation count of CNS Drugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients	185
Comment on: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”	148
The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Ran	140
Unmet Needs in Psychodermatology: A Narrative Review	118
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio	110
Can Leucovorin (Folinic Acid) Treat Autism Features?	89
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing–Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weigh	84
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies	77
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?	65
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines	64
Apixaban for the Treatment of Cerebral Venous Sinus Thrombosis: A Single-Centre Experience and Systematic Review of the Literature	56
Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations	55
The Effect of Psychotropic Medications on Glaucoma Risk and Intraocular Pressure: A Bayesian Meta-Analysis	51
Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials	49
Authors’ Reply to Abudayeh and Fishchenko: Comment on “Early High-Risk Opioid Prescribing and Persistent Opioid Use in Australian Workers with Workers’ Compensation Claims for Back and Neck Musculoske	48
Acknowledgement to Referees	47
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data	45
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine	44
Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders	43
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis	42
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder	40
Managing Chronic Pain: The Ketamine Option	37
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review a	37
The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research	36
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”	36

Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	34
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis	34
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation	33
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia	33
A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder	32
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder	32
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations	32
Comment on “A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder”'	32
Narcolepsy: Beyond the Classic Pentad	32
Therapeutic Use of γ-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy	31
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study	31
Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Re	31
Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Di	30
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges	27
Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study	27
Targeting Kv7 Potassium Channels for Epilepsy	27
Pathological Protein Targets in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapies	26
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of	26
Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide	26
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysi	26
Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”	26
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease	26
Is the Effect of Intensive Antihypertensive Treatment in Acute Intracerebral Hemorrhage Dependent on Hematoma Volume? A Traditional Meta-analysis of the Effect of Antihypertensive Regimens, a Bayesian	26
Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox–Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials	25
Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics	25
International Trends in Opioid Prescribing by Age and Sex from 2001 to 2019: An Observational Study Using Population-Based Databases from 18 Countries and One Special Administrative Region	25
Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease	25
Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review	24
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer’s Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial	24
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis	24
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records	24
Correction: Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	23
Psilocybin and Bipolar Depression: Promise and Prudence	23
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults	23
Efficacy and Safety of Escitalopram Combined with Tandospirone Citrate in Treating Patients with Vascular Depression and Chronic Insomnia: A Randomized Controlled Trial	22
Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options	22
Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research	22
New and Emerging Drug and Gene Therapies for Friedreich Ataxia	21
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease	21
Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	21
Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying Therapy	21
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial	21
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational an	21
Sodium Oxybate: Practical Considerations and Patient Perspectives	20
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis	20
Comment on “Early High-Risk Opioid Prescribing and Persistent Opioid Use in Australian Workers with Workers’ Compensation Claims for Back and Neck Musculoskeletal Disorders or Injuries: A Retrospectiv	20
FcRn Inhibitor Therapies in Neurologic Diseases	20
Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment for Severe Opioid Use Disorder	19
Idiopathic Hypersomnia: Neurobiology, Diagnosis, and Management	19
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders	18

Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy	18
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia	18
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	18
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study	18
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis	17
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study	17
The Effects of Cenobamate and Its Dosage on Cognition: A Retrospective Longitudinal Study in 84 Individuals with Epilepsy	17
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial	17
Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis	17
Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial	17
Pharmacological Frontiers: The Rise of Selective NaV1.8 Inhibition for Pain Management	16
Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial	16
Pharmacological Management of Borderline Personality Disorder and Common Comorbidities	15
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance	15
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease	15
Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study	15
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study	15
Rett Syndrome: The Emerging Landscape of Treatment Strategies	15
Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hype	14
Acknowledgement to Referees	14
Is Crisugabalin Signaling the Arrival of a Third Generation of α2δ Ligands?	14
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use	14
Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010–2025): 15 Years of Progress (or Lack Thereof)	14
Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight	14
Predictors of Esketamine Response in Treatment-Resistant Depression: The Role of Temperament and Cumulative Treatment Resistance	14
Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review	14
Barriers to Safely Discontinuing Duloxetine: An Urgent Call to Action	14
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis	13
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy	13
Effectiveness and Tolerability of Vortioxetine Oral Drops Versus Oral Tablets in Major Depressive Disorder: An Analysis of a Real-World Cohort Study in Switzerland	13
Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke	13
Impulse Control Disorders in Parkinson’s Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management	13
Optimizing Early Antithrombotic Therapy Within 24 Hours of Intravenous Thrombolysis in Acute Ischemic Stroke	13
The Utilization of Low Dose Naltrexone for Chronic Pain	13
Targeting Biometals in Alzheimer’s Disease with Metal Chelating Agents Including Coumarin Derivatives	13
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options	13
Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder	12
Glutamatergic Modulators for Major Depression from Theory to Clinical Use	12
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors	12
Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions	12
Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage	12
Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis	12
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis	12
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study	12
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development	12
Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (	12
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder	12
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study	12
Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studies	12
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studi	12
Author’s Reply to Liu et al.: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”	11
Correction: Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review	11
Update on Neuroprotection after Traumatic Brain Injury	11
Zolpidem May Affect Glial Flow in Addition to Norepinephrine-Mediated Vasomotility of the Glymphatic System	11
Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes	11
Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care	11
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial	11
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study	11
Brexpiprazole for the Treatment of Agitation in Older Adults with Alzheimer’s Disease: A Systematic Review, Bayesian Meta-analysis, and Meta-regression	11
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem	11
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study	10
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation	10
The Options for Neuraxial Drug Administration	10
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinic	10
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies	10
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial	10
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis	10
New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin Landscape	10
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adult	10
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis	10
Motor and Non-motor Complications Following Different Early Therapies in Parkinson’s Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort	10
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults	10
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research	10
Sodium Channel Inhibitors in Clinical Development for Pain Management: A Focused Review	10
Author’s Reply to Zhou et al: Comment on “Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population”	9
Sex Differences in Outcomes of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Preadmission Use of Antiplatelets	9
Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0–3 Versus 4–5: A Secondary Analysis of the ARAMIS Randomized Trial	9
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	9
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors	9
Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review	9

Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data	9
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study	8
Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis	8
Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population	8
Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review	8
The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review	8
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period	8
Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial	7
Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study	7
Clozapine-Related Tachycardia: An Analysis of Incidence	7
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases	7
Circadian Rhythm and Efficacy of Argatroban in Ischemic Stroke with Alteplase: A Post Hoc Analysis of the ARAIS Trial	7
Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial	7
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment	7
Current Principles in the Management of Drug-Resistant Epilepsy	7
A New Dawn in the Management of Narcolepsy	7
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia	7
Patterns of Serum Prolactin Elevation Associated with Nine Second-Generation Antipsychotics in a Large Cohort of Patients with Schizophrenia	7
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action	7
Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022	6
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial	6
Context is a Critical for Psychoactive Drug Effects	6
Prioritizing Antihypertensive Agents in Secondary Prevention of Ischemic Stroke: A Retrospective Population-Based Study	6
Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy	6
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape	6
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets	6
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review	6
Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Con	6
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany	5
A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient’s Perspective	5
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability	5
The State of Synthetic Cannabinoid Medications for the Treatment of Pain	5
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis	5
Psychotropic Drugs Reemerging as Headache Medicines	5
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males	5
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis	5
Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind	5
The Use of Ketamine for the Treatment of Anhedonia in Depression	5
Correction: The Evolution of Anti‑CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function	5